ImmunityBio, Inc. IBRX Reportable Segment — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s reportable segment — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s reportable segment — total revenue?
- ImmunityBio, Inc. (IBRX) reported reportable segment — total revenue of $44.21M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — total revenue changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — total revenue increased by 167.6% year-over-year, from $16.52M to $44.21M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — total revenue?
- Over 3 years (2022 to 2025), ImmunityBio, Inc.'s reportable segment — total revenue has grown at a 678.6% compound annual growth rate (CAGR), from $240K to $113.29M.
- What does reportable segment — total revenue mean?
- Represents the total gross income generated by the specific business segment through its primary operations. This figure reflects the market demand for the segment's products or services before accounting for any associated costs.